专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL183236A Solid pharmaceutical composition of rasagiline 未知
公开(公告)号：IL183236A
公开(公告)日：2014-03-31
申请号：IL18323607
申请日：2007-05-15
申请人： TEVA PHARMA , GILBERT ADRIAN , LICHT DANIELLA , PATASHNIK SHULAMIT
发明人： GILBERT ADRIAN , LICHT DANIELLA , PATASHNIK SHULAMIT

2. 发明专利

IL195724D0 STABLE LAQUINIMOD PREPARATIONS 未知
公开(公告)号：IL195724D0
公开(公告)日：2009-09-01
申请号：IL19572408
申请日：2008-12-04
申请人： TEVA PHARMA , LICHT DANIELA , PATASHNIK SHULAMIT , GILBERT ADRIAN
IPC分类号： A61K20100101
摘要： The invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable salt of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier.

3. 发明专利

IL185420D0 FORMULATIONS OF LADOSTIGIL TARTRATE 未知
公开(公告)号：IL185420D0
公开(公告)日：2008-08-07
申请号：IL18542007
申请日：2007-08-21
申请人： TEVA PHARMA , LIGHT DANIELLA , LOVINGER IOANA , CACIULARU FANNY , GILBERT ADRIAN
IPC分类号： C07C20100101
摘要： The invention relates to a pharmaceutical composition of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and up to 5% by weight of the composition of water. The composition is typically in a solid oral form which upon administration to a human subject provides a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL.

4. 发明专利

IL195724A Stable laquinimod preparations 未知
公开(公告)号：IL195724A
公开(公告)日：2015-09-24
申请号：IL19572408
申请日：2008-12-04
申请人： TEVA PHARMA , LICHT DANIELLA , PATASHNIK SHULAMIT , GILBERT ADRIAN
发明人： LICHT DANIELLA , PATASHNIK SHULAMIT , GILBERT ADRIAN
IPC分类号： A61K20060101 , A61P20060101
摘要： The invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable salt of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier.

5. 发明专利

IL183236D0 RASAGILINE ORALLY DISINTEGRATING COMPOSITIONS 未知
公开(公告)号：IL183236D0
公开(公告)日：2007-09-20
申请号：IL18323607
申请日：2007-05-15
申请人： TEVA PHARMA , GILBERT ADRIAN , LICHT DANIELA , PATASHNIK SHULAMIT
IPC分类号： C07C20100101

6. 发明专利

IL180706D0 PHARMACEUTICAL DOSAGE FORMS INCLUDING RASAGILINE 未知
公开(公告)号：IL180706D0
公开(公告)日：2007-06-03
申请号：IL18070607
申请日：2007-01-15
申请人： TEVA PHARMA , FLESHNER BARAK MOSHE , LERNER ITZHAK , ROSENBERGER VERED , AQUA OFER , GILBERT ADRIAN , LICHT DANIELA , PATASHNIK SHULAMIT
IPC分类号： A61K20100101
摘要： Provided are pharmaceutical dosage forms that include rasagiline formulated and fabricated so that release of rasagiline in the stomach is retarded or inhibited.

7. 发明申请

WO2004064787A3 PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS 审中-公开
标题翻译：用于治疗系统性红斑狼疮的肽的配体配方
公开(公告)号：WO2004064787A3
公开(公告)日：2005-12-15
申请号：PCT/US2004000948
申请日：2004-01-14
申请人： TEVA PHARMA , TEVA PHARMA , COHEN-VERED SHARON , NAFTALI ESMIRA , WEINSTEIN VERA , GILBERT ADRIAN , KLINGER ETY
发明人： COHEN-VERED SHARON , NAFTALI ESMIRA , WEINSTEIN VERA , GILBERT ADRIAN , KLINGER ETY
IPC分类号： A61K20060101 , A61K6/00 , A61K9/00 , A61K9/19 , A61K38/00 , A61K38/08 , A61K38/10 , A61K38/16 , A61K38/17 , A61K39/395 , A61K47/40 , A61P37/00 , C07K7/06 , C07K7/08 , C07K14/47
CPC分类号： C07K7/06 , A61K9/0019 , A61K9/19 , A61K38/1709 , C07K7/08 , C07K14/4713 , C07K2319/00
摘要： The subject invention provides a pharmaceutical composition comprising: an, aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a) peptide comprising at least 12 and at most 30 consecutive amino acids having a sequence corresponding to (i) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a human monoclonal anti-DNA 16/6 Id antibody, or (ii) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease response in mice, or b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, or c) a peptide comprising consecutive amino acids having a sequence of any of and b), or at least two of the sequences in (a)(1), (a) (ii) and (b)(i) through (b)(x), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a) (i), (a) (ii) and (b) (i) through (b)(x); and a solubility enhancer, wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition.
摘要翻译：本发明提供药物组合物，其包含：水性载体; 包含至少12个和至多30个连续氨基酸的a）肽的药学上可接受的盐的0.1mg / ml至20mg / ml的组合物，其具有对应于（i）互补序列中发现的氨基酸序列的序列确定人单克隆抗-DNA 16/6 Id抗体的重链或轻链的确定区（CDR），或（ii）在重或偶联抗体的互补决定区（CDR）内发现的氨基酸序列在小鼠中诱导系统性红斑狼疮（SLE）样疾病反应的致病性抗-DNA单克隆抗体的轻链，或b）包含具有SEQ ID NOS中任一个所示序列的连续氨基酸的肽。（a）（1），（a）（ii）和（b）（i）中的至少两个序列的连续氨基酸的肽，）通过（b）（x），或d）包含连续氨基酸的肽，其具有包含（a）（i），（a）（ii）和（b）（i）至（b）（X）; 和溶解度增强剂，其中肽和溶解度增强剂都溶解在水性载体中; 并且其中所述组合物的pH为4至9，以及通过施用有效量的组合物来减轻人类SLE症状的方法。

8. 发明申请

WO2004064788A3 PARENTERAL FORMULATIONS OF A PEPTIDE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS 审中-公开
标题翻译：用于治疗系统性红斑狼疮的肽的配体配方
公开(公告)号：WO2004064788A3
公开(公告)日：2005-03-24
申请号：PCT/US2004000955
申请日：2004-01-14
申请人： TEVA PHARMA , TEVA PHARMA , COHEN-VERED SHARON , NAFTALI ESMIRA , WEINSTEIN VERA , GILBERT ADRIAN , KLINGER ETY
发明人： COHEN-VERED SHARON , NAFTALI ESMIRA , WEINSTEIN VERA , GILBERT ADRIAN , KLINGER ETY
IPC分类号： A61K20060101 , A61K9/00 , A61K9/19 , A61K31/724 , A61K38/00 , A61K38/10 , A61K39/00 , A61K39/38 , A61K47/40 , A61K47/48 , A61K51/10
CPC分类号： B82Y5/00 , A61K9/0019 , A61K9/19 , A61K31/724 , A61K38/10 , A61K47/6951 , A61K2300/00
摘要： The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula NH2-Gly Tyr Tyr Tip Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-cooH; and a substituted 13-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition ha.s a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition.
摘要翻译：本发明提供包含水性载体的药物组合物; 从0.1mg / ml至20mg / ml组合物的具有结构式NH 2 -Gly Tyr Tyr Tip Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-cooH的药学上可接受的盐; 和有效溶解水的载体中的肽的取代的13-环糊精，其中组合物的pH为4〜9，制备方法和缓解系统性红斑狼疮（SLE）症状的方法人受试者包括向人受试者施用药物组合物。

9. 发明申请

WO2006057912A3 RASAGILINE ORALLY DISINTEGRATING COMPOSITIONS 审中-公开
标题翻译： RASAGILINE ORAZY DISINTEGRATING组合物
公开(公告)号：WO2006057912A3
公开(公告)日：2006-08-17
申请号：PCT/US2005041882
申请日：2005-11-17
申请人： TEVA PHARMA , TEVA PHARMA , PATASHNIK SHULAMIT , LICHT DANIELLA , GILBERT ADRIAN
发明人： PATASHNIK SHULAMIT , LICHT DANIELLA , GILBERT ADRIAN
IPC分类号： A61K31/135
CPC分类号： A61K9/0056 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/135 , A61K31/4166
摘要： This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions.
摘要翻译：本发明提供了包含雷沙吉兰或雷沙吉兰药学上可接受的盐的固体药物组合物，以及具有至少两种糖醇的非丝状微观结构的颗粒。本发明还提供了一种固体药物组合物，其包含雷沙吉兰或雷沙吉兰药学上可接受的盐，崩解剂，流动剂和具有至少两种糖醇的非丝状微结构的颗粒，补充糖醇，辅助流药剂和补充崩解剂。本发明进一步提供了治疗患有帕金森氏病的受试者的方法，包括给予受试者治疗有效量的固体药物组合物，从而治疗受试者。最后，本发明提供了制备这种固体药物组合物的方法。

10. 发明申请

WO2006058250A3 ORALLY DISINTEGRATING COMPOSITIONS 审中-公开
公开(公告)号：WO2006058250A3
公开(公告)日：2006-07-20
申请号：PCT/US2005042809
申请日：2005-11-23
申请人： SPI PHARMA INC , AMIN ARUN F , CHANDAR SARATH , GILBERT ADRIAN , LICHT DANNIT , NORMAN GARY TELFER , PATASHNIK SHULI
发明人： AMIN ARUN F , CHANDAR SARATH , GILBERT ADRIAN , LICHT DANNIT , NORMAN GARY TELFER , PATASHNIK SHULI
IPC分类号： A61K9/20
CPC分类号： A61K9/2018 , A61K9/0056
摘要： This invention provides a solid pharmaceutical composition comprising an active ingredient (e.g., rasagiline) or a pharmaceutically acceptable salt thereof, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising an active ingredient (e.g., rasagiline) or a pharmaceutically acceptable salt thereof, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. Finally, this invention provides a process of making such solid pharmaceutical compositions.
摘要翻译：本发明提供一种固体药物组合物，其包含活性成分（例如雷沙吉兰）或其药学上可接受的盐，以及具有至少两种糖醇的非丝状微结构的颗粒。本发明还提供了一种固体药物组合物，其包含活性成分（例如雷沙吉兰）或其药学上可接受的盐，崩解剂，流动剂和具有至少两种糖醇的非丝状微结构的颗粒的混合物，补充剂糖醇，补充流剂和补充崩解剂。最后，本发明提供制备这种固体药物组合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式